OBAGI Medical Launches Overnight Skin Renewal Cream

OBAGI Medical unveils the latest addition to its professional-grade retinol portfolio, the Retinol + PHA Refining Night Cream.

Formulated with 0.3% Retinol and Polyhydroxy Acid (PHA), this clinically proven, dual-action overnight skin renewal cream provides a resurfaced, smoother, and more even-looking complexion in just 4 weeks*.

The entrapped Retinol 0.3% is a slow-release form of Vitamin A, clinically recognised as a gold-standard ingredient to promote rapid skin cell turnover for a smoother, more radiant complexion. Advanced microspheres shield the Retinol and deliver it slowly into deeper layers of the skin, enhancing results and reducing irritation.

Retinol and PHA work synergistically to refine skin texture and tone, while reducing the appearance of blemishes, fine lines, and wrinkles.

Clinical Trial Results

• Clinically Proven Smoother Texture and More Even-Looking Skin in Just 4 Weeks*
• Visibly Improves Skin Smoothness by 29%.*
• Visibly Improves Skin Tone Evenness by 10%.*
• Reported to be Well-Tolerated.*
• 90% showed visible improvement in smoothness in 4 weeks.*
• 90% noticed the appearance of blemishes was reduced in 4 weeks.*

Key Ingredients

• Entrapped Retinol 0.3% encourages skin cell turnover, visibly resurfaces skin and improves skin tone and texture.
• Polyhydroxy Acid (PHA) provides gentle yet effective exfoliation on the surface of the skin.
• Eight nourishing ingredients including Sodium Hyaluronate, Vitamin E, Squalane, Hydrogenated Lecithin, and Glycerin provide intense hydration, offsetting any potential dryness from the use of Vitamin A.

“Obagi is renowned for retinols that cause minimal irritation with maximum proven clinical results, this is due to an elegant microencapsulation formulation. The introduction of Retinol 0.3% paired with gentle exfoliants and deeply hydrating moisturisers, makes the power of retinol more accessible. This balanced formulation offers an effective yet tolerable entry point for retinol newcomers as well as those who are more hesitant due to skin sensitivity.” - Simone Shoffman, Head of Education and Clinical – HealthXchange

^{*Results based on a 2024 -2025 8-week clinical test. Data on file at Obagi Cosmeceuticals LLC.}